Hypoxia induces a lipogenic cancer cell phenotype via HIF1α-dependent and -independent pathways

Oncotarget

Volumn 6, Issue 4, 2015, Pages 1920-1941

  Valli, Alessandro ^a,b,f   Rodriguez, Miguel ^c,d   Moutsianas, Loukas ^b   Fischer, Roman ^b   Fedele, Vita ^b   Huang, Hong Lei ^b   Van Stiphout, Ruud ^a   Jones, Dylan ^a   Mccarthy, Michael ^b   Vinaxia, Maria ^c,d   Igarashi, Kaori ^e   Sato, Maya ^e   Soga, Tomoyoshi ^e   Buffa, Francesca ^a   Mccullagh, James ^f   Yanes, Oscar ^c,d   Harris, Adrian ^a   Kessler, Benedikt ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^d Biomedical Research Centre in Diabetes   (Spain)

^e KEIO UNIVERSITY   (Japan)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cancer metabolism; Fatty acids; HIF1 ; HIF2 ; Hypoxia; Kennedy pathway; Lipidomics; PAF

Indexed keywords

ACETIC ACID; ACETYL COENZYME A ACETYLTRANSFERASE; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; CHOLINE; GLYCEROL; GLYCEROPHOSPHATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MONOACYLGLYCEROL; MONOUNSATURATED FATTY ACID; OLEIC ACID; OMEGA 3 FATTY ACID; PALMITIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE D; PHOSPHOLIPASE D3; PHOSPHORYLCHOLINE; PLATELET ACTIVATION FACTOR 16; POLYUNSATURATED FATTY ACID; STEARIC ACID; THROMBOCYTE ACTIVATING FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ACAA1 PROTEIN, HUMAN; ACACA PROTEIN, HUMAN; ACETYL COENZYME A ACYLTRANSFERASE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; FATTY ACID; LIPID;

ARTICLE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; FATTY ACID SYNTHESIS; GENE DELETION; HCT116 CELL LINE; HIF1A GENE; HUMAN; HUMAN CELL; HYPOXIA; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLIC REGULATION; METABOLOMICS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; AGED; BIOSYNTHESIS; CELL HYPOXIA; COLORECTAL TUMOR; FEMALE; GENETICS; GENOMICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ACETYL-COA C-ACYLTRANSFERASE; ACETYL-COA CARBOXYLASE; AGED; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FATTY ACIDS; FEMALE; GENOMICS; HCT116 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPID METABOLISM; LIPIDS; MALE; METABOLOMICS; MIDDLE AGED; PLATELET ACTIVATING FACTOR; PROTEOMICS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84922983615     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3058     Document Type: Article

References (78)

1. Schulze A and Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012; 491(7424):364-373.
2. Hsu PP and Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5):703-707.
3. Kroemer G and Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008; 13(6):472-482.
4. Jones NP and Schulze A. Targeting cancer metabolism-aiming at a tumour's sweet-spot. Drug Discov Today. 2012; 17(5-6):232-241.
5. Deberardinis RJ, Sayed N, Ditsworth D and Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008; 18(1):54-61.
6. Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-1033.
7. Menendez JA and Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007; 7(10):763-777.
8. DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell metabolism. 2008; 7(1):11-20.
9. Santos CR and Schulze A. Lipid metabolism in cancer. FEBS J. 2012; 279(15):2610-2623.
10. Accioly MT, Pacheco P, Maya-Monteiro CM, Carrossini N, Robbs BK, Oliveira SS, Kaufmann C, Morgado-Diaz JA, Bozza PT and Viola JP. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res. 2008; 68(6):1732-1740.
11. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW and Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010; 140(1):49-61.
12. Chiang KP, Niessen S, Saghatelian A and Cravatt BF. An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. Chem Biol. 2006; 13(10):1041-1050.
13. Medes G, Thomas A and Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953; 13(1):27-29.
14. Sul HS and Wang D. Nutritional and hormonal regulation of enzymes in fat synthesis: studies of fatty acid synthase and mitochondrial glycerol-3-phosphate acyltransferase gene transcription. Annu Rev Nutr. 1998; 18:331-351.
15. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD and Pasternack GR. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad SciUSA. 1994; 91(14):6379-6383.
16. Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, Park BW and Kim KS. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem. 2007; 282(36):26122-26131.
17. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, Van Poppel H, Baert L, Goossens K, Heyns W and Verhoeven G. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer. 2000; 88(2):176-179.
18. Li JN, Mahmoud MA, Han WF, Ripple M and Pizer ES. Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp Cell Res. 2000; 261(1):159-165.
19. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL and Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad SciUSA. 2000; 97(7):3450-3454.
20. Gao X and Zhang J. Spatiotemporal analysis of differential Akt regulation in plasma membrane microdomains. Mol Biol Cell. 2008; 19(10):4366-4373.
21. Stylli SS, Kaye AH and Lock P. Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci. 2008; 15(7):725-737.
22. Fackler OT and Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol. 2008; 181(6):879-884.
23. Furuta E, Pai SK, Zhan R, Bandyopadhyay S, Watabe M, Mo YY, Hirota S, Hosobe S, Tsukada T, Miura K, Kamada S, Saito K, Iiizumi M, et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res. 2008; 68(4):1003-1011.
24. Berwick DC, Hers I, Heesom KJ, Moule SK and Tavare JM. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem. 2002; 277(37):33895-33900.
25. Kamphorst JJ, Cross JR, Fan J, de Stanchina E, Mathew R, White EP, Thompson CB and Rabinowitz JD. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad SciUSA. 2013; 110(22):8882-8887.
26. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008; 8(9):705-713.
27. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-732.
28. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1):38-47.
29. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010; 20(1):51-56.
30. Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, Kantsevoy SV and Dang LH. Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res. 2006; 66(3):1684-1936.
31. Buffa FM, Harris AL, West CM and Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer. 2010; 102(2):428-435.
32. Kaelin WG, Jr. and Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008; 30(4):393-402.
33. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010; 29(5):625-634.
34. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS and DeBerardinis RJ. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012; 481(7381):385-388.
35. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC and Thompson CB. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad SciUSA. 2011; 108(49):19611-19616.
36. Dang CV. Links between metabolism and cancer. Genes Dev. 2012; 26(9):877-890.
37. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012; 481(7381):380-384.
38. Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wigfield S, Buffa FM, Li JL, Zhang Q, Wakelam MJ, Karpe F, et al. Fatty Acid Uptake and Lipid Storage Induced by HIF-1alpha Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation. Cell Rep. 2014; 9(1):349-365.
39. Fletcher JI, Haber M, Henderson MJ and Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010; 10(2):147-156.
40. Mason P, Liang B, Li L, Fremgen T, Murphy E, Quinn A, Madden SL, Biemann HP, Wang B, Cohen A, Komarnitsky S, Jancsics K, Hirth B, et al. SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids. PLoS One. 2012; 7(3):e33823.
41. Matsumoto K, Taniguchi T, Fujioka Y, Shimizu H, Ishikawa Y and Yokoyama M. Effects of hypoxia on cholesterol metabolism in human monocyte-derived macrophages. Life Sci. 2000; 67(17):2083-2091.
42. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbicki M, Verbeuren TJ, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell metabolism. 2011; 13(4):376-388.
43. Li J, Bosch-Marce M, Nanayakkara A, Savransky V, Fried SK, Semenza GL and Polotsky VY. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1alpha. Physiol Genomics. 2006; 25(3):450-457.
44. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C and Hengstschlager M. The mTOR pathway and its role in human genetic diseases. Mutat Res. 2008; 659(3):284-292.
45. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ and Copland JA. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One. 2010; 5(5):e10696.
46. Jung SY, Jeon HK, Choi JS and Kim YJ. Reduced expression of FASN through SREBP-1 down-regulation is responsible for hypoxic cell death in HepG2 cells. J Cell Biochem. 2012; 113(12):3730-3739.
47. Balasubramanian L and Evens AM. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol. 2006; 18(4):354-359.
48. Chajes V, Joulin V and Clavel-Chapelon F. The fatty acid desaturation index of blood lipids, as a biomarker of hepatic stearoyl-CoA desaturase expression, is a predictive factor of breast cancer risk. Curr Opin Lipidol. 2011; 22(1):6-10.
49. Guillou H, Zadravec D, Martin PG and Jacobsson A. The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice. Prog Lipid Res. 2010; 49(2):186-199.
50. Zhang Y, Wang H, Zhang J, Lv J and Huang Y. Positive feedback loop and synergistic effects between hypoxia-inducible factor-2alpha and stearoyl-CoA desaturase-1 promote tumorigenesis in clear cell renal cell carcinoma. Cancer Sci. 2013; 104(4):416-422.
51. Scaglia N, Caviglia JM and Igal RA. High stearoyl-CoA desaturase protein and activity levels in simian virus 40 transformed-human lung fibroblasts. Biochim Biophys Acta. 2005; 1687(1-3):141-151.
52. von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW and Copland JA. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 2013; 19(9):2368-2380.
53. Miyazaki M, Kim YC, Gray-Keller MP, Attie AD and Ntambi JM. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem. 2000; 275(39):30132-30138.
54. Sarri E, Garcia-Dorado D, Abellan A and Soler-Soler J. Effects of hypoxia, glucose deprivation and acidosis on phosphatidylcholine synthesis in HL-1 cardiomyocytes. CTP:phosphocholine cytidylyltransferase activity correlates with sarcolemmal disruption. Biochem J. 2006; 394(Pt 1):325-334.
55. Mylonis I, Sembongi H, Befani C, Liakos P, Siniossoglou S and Simos G. Hypoxia causes triglyceride accumulation by HIF-1-mediated stimulation of lipin 1 expression. J Cell Sci. 2012; 125(Pt 14):3485-3493.
56. Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C, Tokarska-Schlattner M, Aasum E, Bogdanova A, Perriard E, Perriard JC, Larsen T, Pedrazzini T, et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell metabolism. 2009; 9(6):512-524.
57. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM and Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med. 2002; 8(10):1122-1128.
58. Bansal A, Harris RA and DeGrado TR. Choline phosphorylation and regulation of transcription of choline kinase alpha in hypoxia. J Lipid Res. 2012; 53(1):149-157.
59. Eliyahu G, Kreizman T and Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer. 2007; 120(8):1721-1730.
60. Bougnoux P, Chajes V, Lanson M, Hacene K, Body G, Couet C and Le Floch O. Prognostic significance of tumor phosphatidylcholine stearic acid level in breast carcinoma. Breast Cancer Res Treat. 1992; 20(3):185-194.
61. Ide Y, Waki M, Hayasaka T, Nishio T, Morita Y, Tanaka H, Sasaki T, Koizumi K, Matsunuma R, Hosokawa Y, Ogura H, Shiiya N and Setou M. Human breast cancer tissues contain abundant phosphatidylcholine(36ratio1) with high stearoyl-CoA desaturase-1 expression. PLoS One. 2013; 8(4):e61204.
62. Ishii S and Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res. 2000; 39(1):41-82.
63. Rhee SG. Inositol phospholipids-specific phospholipase C: interaction of the gamma 1 isoform with tyrosine kinase. Trends Biochem Sci. 1991; 16(8):297-301.
64. Chen J, Yang L, Foulks JM, Weyrich AS, Marathe GK and McIntyre TM. Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF synthesis. J Lipid Res. 2007; 48(11):2365-2376.
65. Rankin EB, Rha J, Selak MA, Unger TL, Keith B, Liu Q and Haase VH. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol. 2009; 29(16):4527-4538.
66. Kume K and Shimizu T. Platelet-activating factor (PAF) induces growth stimulation, inhibition, and suppression of oncogenic transformation in NRK cells overexpressing the PAF receptor. J Biol Chem. 1997; 272(36):22898-22904.
67. Denizot Y, Descottes B, Truffinet V, Valleix D, Labrousse F and Mathonnet M. Platelet-activating factor and liver metastasis of colorectal cancer. Int J Cancer. 2005; 113(3):503-505.
68. Melnikova VO, Mourad-Zeidan AA, Lev DC and Bar-Eli M. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem. 2006; 281(5):2911-2922.
69. Xu B, Gao L, Wang L, Tang G, He M, Yu Y, Ni X and Sun Y. Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers. Br J Cancer. 2013; 109(5):1279-1286.
70. Aponte M, Jiang W, Lakkis M, Li MJ, Edwards D, Albitar L, Vitonis A, Mok SC, Cramer DW and Ye B. Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res. 2008; 68(14):5839-5848.
71. Snyder F. Platelet-activating factor: the biosynthetic and catabolic enzymes. Biochem J. 1995; 305 ( Pt 3):689-705.
72. Appleyard CB and Hillier K. Catabolism of platelet-activating factor by human colonic mucosa. Calcium dependence of the catabolizing enzymes. Biochem Pharmacol. 1992; 43(12):2503-2509.
73. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-337.
74. Vinaixa M, Rodriguez MA, Rull A, Beltran R, Blade C, Brezmes J, Canellas N, Joven J and Correig X. Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. J Proteome Res. 2010; 9(5):2527-2538.
75. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H and Soga T. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009; 69(11):4918-4925.
76. Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M and Nishioka T. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res. 2003; 2(5):488-494.
77. Skogerson K, Wohlgemuth G, Barupal DK and Fiehn O. The volatile compound BinBase mass spectral database. BMC Bioinformatics. 2011; 12:321.
78. Fischer R, Trudgian DC, Wright C, Thomas G, Bradbury LA, Brown MA, Bowness P and Kessler BM. Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis. Mol Cell Proteomics. 2012; 11(2):M111 013904.